Oct. 11, 2005 – Arrowhead Research Corp. (Nasdaq:ARWR), a company that funds nanotechnology research and develops companies, announced it accelerated its investment of an additional $3 million to Insert Therapeutics Inc., a majority-owned subsidiary.
The company says its lead anti-cancer drug, IT-101, has showed promise across a wide range of cancers. Insert Therapeutics is currently preparing to enter IT-101 into human clinical trials at the City of Hope Comprehensive Cancer Center in Duarte, Calif.